Davidson Investment Advisors Trims Stock Holdings in Medtronic PLC $MDT

Posted by Brenda Bartman on Aug 30th, 2026

Davidson Investment Advisors lowered its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 4.1% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 348,684 shares of the medical technology company’s stock after selling 15,016 shares during the quarter. Medtronic comprises about 1.1% of Davidson Investment Advisors’ portfolio, making the stock its 23rd largest position. Davidson Investment Advisors’ holdings in Medtronic were worth $27,278,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in MDT. Wedbush Securities Inc. increased its holdings in shares of Medtronic by 5.0% in the second quarter. Wedbush Securities Inc. now owns 52,143 shares of the medical technology company’s stock valued at $4,079,000 after purchasing an additional 2,503 shares during the period. Meiji Yasuda Life Insurance Co boosted its position in Medtronic by 43.0% in the second quarter. Meiji Yasuda Life Insurance Co now owns 24,191 shares of the medical technology company’s stock valued at $1,892,000 after buying an additional 7,278 shares during the last quarter. Thornburg Investment Management Inc. boosted its position in Medtronic by 24.5% in the second quarter. Thornburg Investment Management Inc. now owns 2,511,730 shares of the medical technology company’s stock valued at $196,493,000 after buying an additional 494,653 shares during the last quarter. Hennessy Advisors Inc. increased its holdings in Medtronic by 50.5% in the 2nd quarter. Hennessy Advisors Inc. now owns 90,326 shares of the medical technology company’s stock worth $7,066,000 after buying an additional 30,326 shares during the period. Finally, Sheets Smith Wealth Management acquired a new position in Medtronic in the 2nd quarter worth approximately $387,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Price Performance

NYSE:MDT opened at $91.28 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The company has a 50 day moving average price of $85.57 and a 200-day moving average price of $85.67. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The firm has a market cap of $116.84 billion, a price-to-earnings ratio of 24.47, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. During the same quarter last year, the business earned $1.62 earnings per share. The firm’s revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts forecast that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.2%. Medtronic’s dividend payout ratio (DPR) is 77.21%.

Analysts Set New Price Targets

MDT has been the subject of several research reports. Royal Bank Of Canada restated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. BTIG Research reiterated a “buy” rating and issued a $91.00 price objective on shares of Medtronic in a research note on Tuesday, August 18th. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a report on Thursday, June 4th. UBS Group upgraded shares of Medtronic from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $100.00 in a research report on Tuesday, July 28th. Finally, Truist Financial cut their price target on Medtronic from $95.00 to $86.00 and set a “hold” rating on the stock in a research report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $99.79.

Check Out Our Latest Stock Report on MDT

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Needham raised its price target to $114 from $101 and reiterated a “Buy” rating, implying substantial upside from recent trading levels. The firm reportedly expects Medtronic to beat first-quarter estimates and raise its fiscal 2027 guidance. Needham raises Medtronic price target
Positive Sentiment: Analysts see potential for Medtronic to exceed consensus first-quarter expectations of approximately $1.39 in adjusted EPS and $9.54 billion in revenue. A stronger-than-expected report could support the shares, particularly if management lifts its fiscal 2027 outlook. Medtronic earnings estimates
Positive Sentiment: Recent coverage highlights momentum in Medtronic’s cardiovascular businesses and growth in renal denervation, while broader device demand is supporting the company’s rebound narrative. Medtronic device momentum
Neutral Sentiment: The imminent earnings release is likely to keep volatility elevated. Investors will evaluate quarterly performance, procedure trends, and management’s fiscal 2027 guidance for confirmation that the recovery is sustainable. Medtronic rebound outlook
Negative Sentiment: Tariff exposure and unfavorable currency movements remain potential headwinds to margins and reported growth. These risks could limit the benefit of strong cardiovascular trends or weigh on the shares if management issues cautious guidance. Medtronic portfolio outlook

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 4,189 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Medtronic Profile

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).